Form 4 for NAMS NewAmsterdam Pharma Co N.V.
Accepted 2025-03-26 00:00:00 ET · period of report 2025-03-24 · accession 0000950170-25-045283 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2025-03-26 | 2025-03-24 | NAMS | Kastelein Johannes Jacob Pieter | CSO, Dir | M - OptEx | — | +150.0K | 150.0K | New | — |
| DI | 2025-03-26 | 2025-03-24 | NAMS | Kastelein Johannes Jacob Pieter | CSO, Dir | M - OptEx | $0.00 | -150.0K | 820.2K | -15% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-03-24 | M | A | 150,000 | — | 150,000 | I See footnote | — | — | (F1) The exercise price of the option is 1.16392 Euros. (F2) The Ordinary Shares are held by Futurum B.V. ("Futurum") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the Ordinary Shares held by Futurum. |
| 2 | Derivative | Option (right to buy) | 2025-03-24 | M | D | 150,000 | $0.00 | 820,229 | I See footnote | — · — to 2031-07-06 | 150,000 Ordinary Shares | (F4) The option was granted to and is held by Futurum through NAP PoolCo B.V. ("PoolCo") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the issuer. (F1) The exercise price of the option is 1.16392 Euros. (F3) The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |